Correction to: Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4
Journal of Experimental & Clinical Cancer Research volume 38, Article number: 443 (2019)
Correction to: J Exp Clin Cancer Res (2019) 38: 409
In the original publication of this article , the author would like to revise Fig. 4.
In this article, the authors explored the relationship between the expression level of TRIP13 and EMT markers (E-cadherin, vimentin, snail) in their HCC tissue microarray (Fig. 4e), and this tissue microarray was also used in their preciously published article in Journal of Experimental & Clinical Cancer Research (Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma. Doi: https://doi.org/10.1186/s13046-019-1113-3. (Fig. 3e)). Unfortunately, the authors of these two articles selected and displayed immunohistochemical images of the same patient without knowing it. In order to make the article more rigorous, the authors of this article replaced Fig. 4 with another patient’s immunohistochemical images. The revised Fig. 4 is shown below:
The authors sincerely apologize for the inconvenience caused to the readers.
Zhu MX, et al. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. J Exp ical Cancer Res. 2019;38:409. https://doi.org/10.1186/s13046-019-1401-y.
About this article
Cite this article
Zhu, MX., Wei, CY., Zhang, PF. et al. Correction to: Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. J Exp Clin Cancer Res 38, 443 (2019). https://doi.org/10.1186/s13046-019-1454-y